Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05719701
Other study ID # ICP-CL-01101
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 29, 2023
Est. completion date December 30, 2025

Study information

Verified date March 2024
Source Beijing InnoCare Pharma Tech Co., Ltd.
Contact April Huang
Phone 010-66609723
Email April.huang@innocarepharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed and/or refractory multiple myeloma.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 30, 2025
Est. primary completion date July 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Aged = 18 years old. 2. Diagnosed as relapsed and/or refractory multiple myeloma .The patient must have measurable diseases.Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2. 3. Patients must have adequate organ function. Expected survival time = 6 months. 4. All toxicities caused by prior anticancer therapy must have recovered to Grade = 1 (based on CTCAE v5.0) except alopecia and fatigue. Female patients of childbearing potential should have a negative blood pregnancy test result within 48 h prior to the first dose of investigational drug. Exclusion Criteria: 1. Known active central nervous system (CNS) involvement or history of the disease, or clinical signs of multiple myeloma meningeal/spinal meningeal involvement. 2. Patients with solitary plasmacytoma; plasma cell leukemia (PCL) (active PCL or history of PCL); Waldenström's macroglobulinemia; POEMS syndrome or symptomatic amyloidosis. 3. Prior active or history of malignancies other than MM, occurring within 5 years prior to the first dose of investigational drug, with the exception of radically treated local curable cancers. 4. Uncontrolled or severe cardiovascular disorders. 5. Any active infection within 14 days prior to the first dose of investigational drug. 6. Patients with diseases restricted from participation as described in the protocol 7. Having undergone major surgery within 28 days prior to the first dose of investigational drug, or minor surgery within 2 weeks prior to the first dose. Any severe or uncontrolled systemic disease evaluated by investigatorthat may increase the risk associated with study participation and drug administration or affect the patient's ability to receive the investigational drug. 8. Patients who have received any other systemic treatment, anti-tumor traditional Chinese (herbal) medicine therapy , and any other investigational drug therapy for MM within 28 days or 5 half-lives of the drugs (whichever is shorter) prior to the first dose of investigational drug. 9. Patients who have received systemic treatment with corticosteroids or other immunosuppressive drugs within 14 days prior to the first dose of investigational drug. Subjects are allowed to use topical, ocular, intra-articular, intranasal, and inhaledcorticosteroid ; short-term use (= 7 days) of corticosteroid for prophylaxis (e.g., contrast agent allergy) or for the treatment of non-autoimmune diseases (e.g., delayed hypersensitivity reaction caused by contact allergens) is permitted. 10. Patients who have received medications or foods with strong inhibitory or inductive effects on cytochrome P450 CYP3A, and proton pump inhibitorswithin 2 weeks prior to the first dose of investigational drug, or are planning to receive them during the study. 11. Patients with a history of severe allergic reactions to IMIDs , or dexamethasone, or to any component contained in ICP-490 or dexamethasone formulation (CTCAE V5.0 Grade > 3).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ICP-490
Several dose groups of ICP-490 are planned for the dose exploration.
Dexamethasone
Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.

Locations

Country Name City State
China Peking University People's Hospital Beijing Beijing
China Sun Yat-sen University Cancer Center Guangzhou Guangdong
China The First Affiliated Hospital,Zhejiang University School of Medicine Hangzhou Zhejiang
China Renji Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Shanghai
China Shengjing Hospital of China Medical University Shenyang Liaoning
China Henan Cancer Hosptital Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
Beijing InnoCare Pharma Tech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase I : Incidence, type, and severity of adverse events (AEs) as judged according to NCI-CTCAE V5.0 AE refers to any adverse event occurring in subjects during clinical research period. The incidence and type of AEs will be evaluated and the severity will be judged according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version5.0. Through study completion, an average of 3 years
Primary Phase I : Incidence, type, and severity of dose-limiting toxicities (DLTs) The dose-limiting toxicity (DLT) assessed in the phase I dose exploration study is defined as AEs related to study treatment that meet the following criteria (according to the NCI CTCAE v5.0 criteria) and occur in Cycle 1. Through study completion, an average of 3 years
Primary Phase I : RP2Ds and/or MTDs Phase I is the dose exploration study of ICP-490 to preliminarily determine RP2Ds (probably more than one) and MTD (if applicable). MTD: The dose level corresponding to the dose group whose posterior probability of DLT incidence estimated by PAVA (pool adjacent violators algorithm) is closest to the target toxicity probability (25%). Through study completion, an average of 3 years
Primary Phase II : ORR (defined as sCR + CR + VGPR + PR) assessed according to IMWG criteria. Disease response will be assessed according to the 2016 IMWG response criteria. Through study completion, an average of 3 years
Secondary Maximum concentration (Cmax) Maximum concentration (Cmax) will be calculated through multiple plasma concentrations drawn from the patients after administration. Through study completion, an average of 3 years
Secondary Time to maximum concentration (Tmax) Time to maximum concentration (Tmax) will be calculated through multiple plasma concentrations drawn from the patients after administration. Through study completion, an average of 3 years
Secondary Half-life (T1/2) Half-life (T1/2) will be calculated through multiple plasma concentrations drawn from the patients after administration. Through study completion, an average of 3 years
Secondary Area under the concentration-time curve (AUC0-8 and AUC0-t) Area under the concentration-time curve (AUC0-8 and AUC0-t) will be calculated through multiple plasma concentrations drawn from the patients after administration. Through study completion, an average of 3 years
Secondary Apparent clearance (CL/F) Apparent clearance (CL/F) will be calculated through multiple plasma concentrations drawn from the patients after administration. Through study completion, an average of 3 years
Secondary Apparent volume of distribution during terminal phase (Vz/F) Apparent volume of distribution during terminal phase (Vz/F) will be calculated through multiple plasma concentrations drawn from the patients after administration. Through study completion, an average of 3 years
Secondary Steady-state PK parameters Steady-state PK parameters will be calculated through multiple plasma concentrations drawn from the patients after administration. Through study completion, an average of 3 years
Secondary The overall response rate (ORR) assessed according to the International Myeloma Working Group (IMWG) criteria (ORR, defined as stringent complete response (sCR) + complete response (CR) + very good partial response (VGPR) + partial response (PR)) Disease response will be assessed according to the 2016 IMWG response criteria. Through study completion, an average of 3 years
Secondary Phase I & IIa : Complete response rate (CRR, defined as sCR + CR) assessed according to IMWG criteria Disease response will be assessed according to the 2016 IMWG response criteria. Through study completion, an average of 3 years
Secondary Phase I & IIa : Very good or better partial response rate assessed according to IMWG criteria (= VGPR rate, defined as VGPR + sCR + CR) Disease response will be assessed according to the 2016 IMWG response criteria. Through study completion, an average of 3 years
Secondary Phase I & IIa : Time to response (TTR) assessed according to IMWG criteria Disease response will be assessed according to the 2016 IMWG response criteria Through study completion, an average of 3 years
Secondary Phase I & IIa : Duration of response (DOR) assessed according to IMWG criteria Disease response will be assessed according to the 2016 IMWG response criteria Through study completion, an average of 3 years
Secondary Phase I & IIa : Progression-free survival (PFS) assessed according to IMWG criteria Disease response will be assessed according to the 2016 IMWG response criteria Through study completion, an average of 3 years
Secondary Phase I & IIa : Overall survival (OS) The follow-up visits should be carried out every 12 weeks after the last dose via telephone or other methods to obtain the survival status information of patients. Through study completion, an average of 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT03140943 - Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 2
Recruiting NCT05066022 - A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma N/A
Recruiting NCT06182696 - OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM Phase 1/Phase 2
Recruiting NCT03715478 - Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex Phase 1/Phase 2
Completed NCT02917941 - A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma Phase 2
Not yet recruiting NCT03903406 - Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study
Completed NCT03242460 - The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) Phase 2
Terminated NCT03836053 - Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma Phase 1
Recruiting NCT05297240 - Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
Terminated NCT04272775 - A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Phase 1
Not yet recruiting NCT06351644 - ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 1/Phase 2
Withdrawn NCT04392648 - A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Phase 1
Active, not recruiting NCT01632150 - Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Phase 2
Completed NCT02831686 - A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma Phase 1
Recruiting NCT06153251 - A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma Phase 1
Completed NCT00882063 - Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma Phase 1/Phase 2
Terminated NCT04017130 - A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT03416374 - A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Phase 4
Recruiting NCT05486975 - This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma. Early Phase 1
Completed NCT03170882 - A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma Phase 2